Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva’s strong biosimilars portfolio, in line with Teva's Pivot to Growth StrategyThe approvals underscore Teva’s commitment to broadening access to biosimilars TEL AVIV, Israel, Nov. 25, 2025 ...

Neilson Barnard / Getty Images Entertainment via Getty Images Quick Read Druckenmiller produced 30% average annual returns with no losing years at Duquesne from 1981 to 2010. Natera (NTRA) revenue rose 35% year-over-year in Q3 2025 and beat analyst estimates by 14%. Insmed (INSM) stock surged from below $26 in May 2024 to nearly $200 with revenue growing 52% year-over-year in Q3 2025. If you’re thinking about retiring or know someone who is, there are three quick questions causing many Americans t ...

The Tel Aviv Stock Exchange fell today. The Tel Aviv 35 Index fell 1.15% to 3,320.72 points, the Tel Aviv 125 Index fell 1.20% to 3,359.47 points; and the BlueTech Global Index fell 1.36% to 574.59 points. The All Bond corporate bond index rose 0.09% to 419.78 points. Turnover totalled NIS 1.54 billion in equities and NIS 1.97 billion in bonds. On the foreign exchange market, the representative shekel-dollar rate was set 0.644% higher on Friday, at NIS 3.28/$, and the representative shekel-euro rate was s ...

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows: 8th Annual Evercore Healthcare ConferenceWednesday, December 3, 2025, at 8:20 A.M. Eastern Time (ET)Piper Sandler 37th Annual Healthcare ConferenceWednesday, December 3, 2025, at 11:00 A.M. Eastern Time (ET)Citi’s 2025 G ...

Core Insights - Teva Pharmaceutical Industries Ltd. will present at three investor conferences in December 2025, featuring CEO Richard Francis and other executive management [1][5] - The company is transitioning into a leading innovative biopharmaceutical firm, supported by a strong generics business, with a focus on neuroscience, immunology, complex generics, biosimilars, and pharmacy brands [3] Company Overview - Teva has been committed to improving health for over 120 years, emphasizing innovation and addressing patient needs [3] - The company aims to expand its innovative and biosimilar medicines pipeline while maintaining its generic medicines portfolio [4]

Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceutical... ...

Teva Launches Teva Rise Teva Launches Rise - Global Open Innovation Platform First cohort features 7 real-world challenges across R&D, manufacturing and supply chain, commercial and medical affairs Teva's first-ever global innovation platform aims to accelerate patient impact and drive business transformation, as part of its Pivot to Growth StrategyRise will enable startups and tech players worldwide to validate their solutions in real-world settings, scaling impact across Teva's global ecosystem incl ...

Teva Pharmaceutical Industries (NYSE:TEVA) 2025 Conference November 18, 2025 06:00 AM ET Company ParticipantsRichard Francis - CEOConference Call ParticipantsDennis Ding - Biotech and Pharma AnalystDennis DingWelcome to the Jefferies London Healthcare Conference. My name is Dennis Ding, Biotech and Pharma Analyst here at Jefferies, and I have the wonderful pleasure of having Richard Francis here, CEO of Teva. Welcome.Richard FrancisThank you. Thank you very much for having me.Dennis DingObviously, you know, ...

Market Performance - The Tel Aviv Stock Exchange saw a rise today, with the Tel Aviv 35 Index increasing by 0.38% to a record 3,447.17 points and the Tel Aviv 125 Index rising by 0.41% to 3,505.73 points [1] - The All Bond corporate bond index rose by 0.04% to 419.53 points, while the BlueTech Global Index fell by 0.92% to 597.63 points [1] - Total turnover in equities reached NIS 1.42 billion and NIS 2.40 billion in bonds [1] Currency Exchange Rates - The shekel-dollar rate was set 0.81% higher at NIS 3.235/$, and the shekel-euro rate was set 0.926% higher at NIS 3.761/€ [2] Notable Stock Movements - Nice (Nasdaq: NICE; TASE:NICE) experienced the largest increase on the Tel Aviv 35 Index, rising by 5.61% [2] - Other notable gainers included Navitas Petroleum LP (TASE: NVPT) with a rise of 5.04% and Clal Insurance Enterprise Holdings (TASE: CLIS) increasing by 3.31% [2] - Elbit Systems Ltd. (Nasdaq: ESLT; TASE: ESLT) rose by 0.50% [2] Banking Sector Performance - Bank Hapoalim (TASE: POLI) led the market with a rise of 1.59% and the highest trading turnover [3] - Other banks also saw gains, with Bank Leumi (TASE: LUMI) rising by 1.27%, Mizrahi Tefahot Bank increasing by 1.55%, and Israel Discount Bank (TASE: DSCT) rising by 2.19% [3] Declining Stocks - Camtek (Nasdaq: CAMT; TASE: CAMT) had the largest decline on the Tel Aviv 35 Index, falling by 4.73% [3] - Other notable decliners included Tower Semiconductor Ltd. (Nasdaq: TSEM; TASE: TSEM) down by 4.08%, Nova Ltd. (Nasdaq: NVMI; TASE: NVMI) down by 3.89%, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) down by 2.47% [3]

Core Insights - Duquesne Family Office, led by Stanley Druckenmiller, filed its third-quarter 13F, showcasing a dynamic and actively managed portfolio that emphasizes agile asset allocation [1][2] - The filing reflects Druckenmiller's ongoing pursuit of growth and value, with a notable increase in new positions while exiting others, consistent with the firm's nimble investment strategy [2] Holdings Summary - New significant positions include Amazon.com Inc. (437,070 shares), Cleveland-Cliffs Inc. (2,715,035 shares), Alphabet, Inc. (102,200 shares), Meta Platforms Inc. (76,100 shares), and StubHub Holdings, Inc. (4,259,516 shares) [5] - The firm closed several positions, including Microsoft Corp. (sold 200,930 shares), Eli Lilly & Co (sold 100,675 shares), Viking Therapeutics Inc. (sold 549,295 shares), Applovin Corp. (sold 76,100 shares), and Joby Aviation Inc. (sold 31,489 shares) [5] - As of September 30, 2025, the firm's top five holdings were Natera Inc. (13%), Insmed Inc. (8.6%), Teva Pharmaceutical Industries Ltd. (8.3%), Taiwan Semiconductor Manufacturing Company Ltd. (5.3%), and Woodward Inc. (3.9%) [5] Investment Strategy - Duquesne's aggressive repositioning in the third quarter reinforces its reputation for nimble action and readiness to capture growth opportunities, particularly in the healthcare and technology sectors [2]